Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC

Introduction: In patients with NSCLC harboring oncogenic ALK or ROS1 rearrangements, tyrosine kinase inhibitors have yielded high response rates and improvements in progression-free survival compared with cytotoxic chemotherapy; however, acquired resistance eventually develops. In preclinical models...

Full description

Bibliographic Details
Main Authors:	Matthew S. Lara, BS, Matthew A. Gubens, MD, Bianca Bacaltos, MS, Lea Daran, BA, Steffany L. Lim, BS, Tianhong Li, MD, David R. Gandara, MD, Trever G. Bivona, MD, PhD, Jonathan W. Riess, MD, Collin M. Blakely, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	JTO Clinical and Research Reports
Subjects:	Ceritinib Trametinib ALK-rearrangement ROS1-rearrangment Non–small cell lung cancer MEK inhibition
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364322001606

Similar Items

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib
by: Yuki Matsumura, et al.
Published: (2021-08-01)

Neoadjuvant ceritinib treatment in ALK‐rearranged locally advanced adenosquamous carcinoma: A case report
by: Shixiong Mai, et al.
Published: (2022-08-01)

Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
by: Hui Li, et al.
Published: (2022-08-01)

Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib
by: Marco Caruana, MD, et al.
Published: (2020-10-01)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of <i>ALK</i>-Rearranged NSCLC: <i>ALK</i>- and <i>BRAF</i>-Mutations Followed by Epithelial-Mesenchymal Transition
by: Edyta M. Urbanska, et al.
Published: (2020-04-01)

Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation
by: Kyaw Zwar Myint, et al.
Published: (2024-02-01)

Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer
by: K. K. Laktionov, et al.
Published: (2019-06-01)

Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
by: Olaf Beck, et al.
Published: (2020-03-01)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
by: Rothschild SI
Published: (2016-05-01)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
by: Jain RK, et al.
Published: (2017-10-01)

ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Growth of Triple-Negative Breast Cancer Cells
by: Bora Lim, et al.
Published: (2021-10-01)

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
by: Weart TC, et al.
Published: (2018-04-01)

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer
by: Steven H Lin, et al.
Published: (2022-01-01)

Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer
by: Yuke TIAN, et al.
Published: (2020-08-01)

Case Report: Patient With Lung Adenocarcinoma With ALK-HLA-DRB1 Rearrangement Shows Impressive Progression-Free Survival After Sequential Crizotinib and Ceritinib Treatment
by: Peng Gao, et al.
Published: (2022-02-01)

Severe Lymphatic Disorder and Multifocal Atrial Tachycardia Treated with Trametinib in a Patient with Noonan Syndrome and SOS1 Mutation
by: Michele Lioncino, et al.
Published: (2022-08-01)

Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors
by: Amanda J.W. Gibson, BSc (Hons), et al.
Published: (2021-04-01)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
by: Kathryn C. Arbour, MD, et al.
Published: (2022-01-01)

Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights
by: Giulia Chiabotto, et al.
Published: (2020-06-01)

Combined Lorlatinib, Dabrafenib, and Trametinib Treatment for ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer with a Lorlatinib-Induced BRAF V600E Mutation: A Case Report
by: Li D, et al.
Published: (2022-11-01)

Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma
by: Wei Wang, et al.
Published: (2021-09-01)

Crystallization Behavior of Ceritinib: Characterization and Optimization Strategies
by: Iva Zokić, et al.
Published: (2023-09-01)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
by: Santarpia M, et al.
Published: (2017-07-01)

Ceritinib is a novel triple negative breast cancer therapeutic agent
by: Shengli Dong, et al.
Published: (2022-06-01)

A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01
by: Sébastien Perreault, et al.
Published: (2019-12-01)

Ceritinib‐associated hyperglycemia in the Japanese Adverse Drug Event Report Database
by: Haruka Fujita, et al.
Published: (2020-05-01)

The WNK1–ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib
by: Adrián Sánchez‐Fdez, et al.
Published: (2023-04-01)

Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
by: Tung Hoang, et al.
Published: (2020-02-01)

The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway
by: Juri Ogishima, et al.
Published: (2018-12-01)

ALK, ROS1 and EGFR status of lung cancers in the Aegean Region of Turkey
by: Gulden Diniz, et al.
Published: (2022-01-01)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
by: Chiara Pisano, et al.
Published: (2022-01-01)

Thoracic SMARCA4-Deficient Undifferentiated Tumor With ALK Fusion Treated With Alectinib Achieved Remarkable Tumor Regression: Case Report
by: Jin Sheng, MD, et al.
Published: (2023-04-01)

BRAF Inhibitors in Non-Small Cell Lung Cancer
by: Vincenzo Sforza, et al.
Published: (2022-10-01)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
by: Fangfang Gao, et al.
Published: (2022-04-01)

Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report
by: Po-Lan Su, MD, et al.
Published: (2021-08-01)

Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report
by: Zhongxing Bing, et al.
Published: (2021-07-01)

Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation
by: Wenxin He, et al.
Published: (2022-11-01)

Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
by: Francisco Meraz-Torres, et al.
Published: (2024-01-01)

Response to a Combination of Full-Dose Osimertinib and Ceritinib in a Non-Small Cell Lung Cancer Patient with EML4-ALK Rearrangement and Epidermal Growth Factor Receptor Co-Mutation
by: Thai Hoa Thi Nguyen, et al.
Published: (2021-07-01)

P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
by: Ryohei Katayama, et al.
Published: (2016-01-01)